Clinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy: State-of-the-Art Review.
Methamphetamine-associated cardiomyopathy (MACM) is an increasingly recognized disease entity in the context of a rapidly spreading methamphetamine epidemic. MACM may afflict individuals with a wide range of ages and socioeconomic backgrounds. Presentations can vary greatly and may involve several complications unique to the disease. Given the public health significance of this disease, there is a relative dearth of consensus material to guide clinicians in understanding, diagnosing, and managing MACM. This review therefore aims to: (1) describe pathologic mechanisms of methamphetamine as they pertain to the development, progression, and prognosis of MACM, and the potential to recover cardiac function; (2) summarize existing data from epidemiologic studies and case series in an effort to improve recognition and diagnosis of the disease; (3) guide short- and long-term management of MACM with special attention to expected or potential sequelae of the disease; and (4) highlight pivotal unanswered questions in need of urgent investigation from a public health perspective.
['Reddy|Pavan K V|PKV|', 'Ng|Tien M H|TMH|', 'Oh|Esther E|EE|', 'Moady|Gassan|G|', 'Elkayam|Uri|U|']
D019969:Amphetamine-Related Disorders D000818:Animals D009202:Cardiomyopathies D000697:Central Nervous System Stimulants D006321:Heart D006801:Humans D008694:Methamphetamine D011237:Predictive Value of Tests D020127:Recovery of Function D012307:Risk Factors D016896:Treatment Outcome
management cardiomyopathy methamphetamine diagnosis heart failure